Abstract
During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.
Keywords: Inflammation, anti-inflammatory drug, p38 MAPK, IL-6, JAK/STAT, PI3K, hippo pathway.
Current Pharmaceutical Design
Title:Signaling Pathways in Inflammation and Anti-inflammatory Therapies
Volume: 24 Issue: 14
Author(s): Yiu To Yeung, Faisal Aziz, Angelica Guerrero-Castilla and Sandro Arguelles*
Affiliation:
- Department of Physiology, Faculty of Pharmacy, University of Seville, Seville,Spain
Keywords: Inflammation, anti-inflammatory drug, p38 MAPK, IL-6, JAK/STAT, PI3K, hippo pathway.
Abstract: During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.
Export Options
About this article
Cite this article as:
Yeung To Yiu , Aziz Faisal, Guerrero-Castilla Angelica and Arguelles Sandro *, Signaling Pathways in Inflammation and Anti-inflammatory Therapies, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180327165604
DOI https://dx.doi.org/10.2174/1381612824666180327165604 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Role of Dietary Fiber and Short-Chain Fatty Acids in the Colon
Current Pharmaceutical Design Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design The Pharmacological Treatment of Cachexia
Current Drug Targets Studying Interactions of Drugs with Cell Membrane Nutrient Transporters: New Frontiers of Proteoliposome Nanotechnology
Current Pharmaceutical Design Synthesis and Characterization of Oxazolopyridine and Benzoxazole Derivatives
Letters in Organic Chemistry Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Consumption of Cooked Navy Bean Powders Modulate the Canine Fecal and Urine Metabolome
Current Metabolomics Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Recent Progress in the Development of Selective TRPV1 Antagonists for Pain
Current Topics in Medicinal Chemistry The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents